Pseudo-PDT in Central Serous Chorioretinopathy

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02799992

Enrollment

Registered

2016-06-15

Start date

2016-06-30

Completion date

2016-09-30

Last updated

2016-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Central Serous Chorioretinopathy

Brief summary

Acute central serous chorioretinopathy (CSC) is a common disorder in middle-aged patients, characterized by serous retinal detachment in the macular region. We evaluated half-dose verteporfin photodynamic therapy (hd-PDT) versus 689 nm laser treatment in chronic CSC. Twenty-two eyes of 22 patients with symptomatic chronic CSC were randomized in a 1:1 ratio to receive hd-PDT (group 1) or 689-LT delivering 95 J/cm2 by application of an intensity of 805 mW/cm2 over 118 seconds. Best-corrected visual acuity (BCVA) and spectral-domain optical coherence tomography findings were compared between groups.

Interventions

PROCEDURE689 nm Laser Treatment of the Macula

PROCEDUREHalf Dose Photodynamic Therapy

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* age ≥18 years; * patients with best-corrected visual acuity (BCVA) of 20/200 or better; * presence of subretinal fluid (SRF) and/or serous pigment epithelial detachment involving the fovea on optical coherence tomography (OCT); * presence of active angiographic leakage in fluorescein angiography caused by CSC and no other diseases, and abnormal dilated choroidal vasculature and other features in indocyanine green angiography (ICGA) consistent with the diagnosis of CSC.

Exclusion criteria

* any previous treatment for CSC; * evidence of choroidal neovascularization or other maculopathy on fundus examination.

Design outcomes

Primary

Measure	Time frame	Description
Best-corrected Visual Acuity (LogMAR)	6 months	Measured with ETDRS chart
Central Retinal Thickness (micron)	6 months	Measured with OCT
Subfoveal Choroidal Thickness (micron)	6 months	Measured with OCT

Secondary

Measure	Time frame	Description
Ellipsoid Zone Recovery (integrity of IS/OS line)	6 months	As visible with OCT scans

Contacts

Primary ContactAndrea Russo, MD, PhD

dott.andrea.russo@gmail.com+390303995308

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026